Karl L.M. Rothweiler
Fondateur chez Aglaia Management BV
Profil
Mr. Rothweiler is a partner in Entity Holding B.V., an early-stage venturing company that he co-founded in 1995.
He has been involved in the founding, restructuring and funding of multiple technology driven companies.
Mr. Rothweiler’s management experience is derived from his time with Cap Gemini, where he held the position of Director of the Finance Division with a staff of 650 prior to founding Entity.
Mr. Rothweiler received his MBA from the University of Georgia, following his study at The Netherlands School of Business, Nijenrode.
Before co-founding Aglaia Biomedical Ventures, Karl Rothweiler was involved in the founding, restructuring and funding of multiple technology driven companies.
After completing his studies at The Netherlands School of Business Nijenrode, he received his MBA from the University of Georgia (USA).
Postes actifs de Karl L.M. Rothweiler
| Sociétés | Poste | Début |
|---|---|---|
Aglaia Management BV
 Aglaia Management BV Investment ManagersFinance Aglaia Management BV is an independent venture capital investment firm headquartered in Bilthoven, the Netherlands. In 2003, Aglaia was co-founded by Mark Krul and Karl Rothweiler. | Fondateur | 01/01/2003 |
Anciens postes connus de Karl L.M. Rothweiler
| Sociétés | Poste | Fin |
|---|---|---|
Modra Pharmaceuticals BV
 Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Modra Pharmaceuticals BV designs and develops oral formulations of commonly used anti-cancer drugs. It is a clinical-stage company which develops series of oral formulations of existing IV anticancer drugs which reduce the side effects common to IV formulations, thereby improving patient convenience. The company was founded in June 2010 and is headquartered in Amsterdam, the Netherlands. | Directeur/Membre du Conseil | - |
ORCA Therapeutics BV
 ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | Directeur/Membre du Conseil | - |
ISA Pharmaceuticals BV
 ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Directeur/Membre du Conseil | - |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Directeur Financier/CFO | - |
Formation de Karl L.M. Rothweiler
| University of Georgia | Masters Business Admin |
| Nyenrode Business Universiteit | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Aglaia Management BV
Aglaia Management BV Investment ManagersFinance Aglaia Management BV is an independent venture capital investment firm headquartered in Bilthoven, the Netherlands. In 2003, Aglaia was co-founded by Mark Krul and Karl Rothweiler. | Finance |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
ISA Pharmaceuticals BV
ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Health Technology |
Modra Pharmaceuticals BV
Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Modra Pharmaceuticals BV designs and develops oral formulations of commonly used anti-cancer drugs. It is a clinical-stage company which develops series of oral formulations of existing IV anticancer drugs which reduce the side effects common to IV formulations, thereby improving patient convenience. The company was founded in June 2010 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
